Ligand Pharmaceuticals Net Income 2006-2021 | LGND

Ligand Pharmaceuticals net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Ligand Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-3
2019 $629
2018 $143
2017 $13
2016 $-2
2015 $230
2014 $12
2013 $11
2012 $-1
2011 $10
2010 $-10
2009 $-2
2008 $-98
2007 $282
2006 $-32
2005 $-36
Ligand Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $14
2021-06-30 $31
2021-03-31 $18
2020-12-31 $6
2020-09-30 $-7
2020-06-30 $22
2020-03-31 $-24
2019-12-31 $-7
2019-09-30 $-15
2019-06-30 $-14
2019-03-31 $666
2018-12-31 $-42
2018-09-30 $67
2018-06-30 $73
2018-03-31 $45
2017-12-31 $-7
2017-09-30 $8
2017-06-30 $6
2017-03-31 $5
2016-12-31 $-3
2016-09-30 $1
2016-06-30 $-6
2016-03-31 $7
2015-12-31 $6
2015-09-30 $199
2015-06-30 $24
2015-03-31 $1
2014-12-31 $7
2014-09-30 $1
2014-06-30 $2
2014-03-31 $2
2013-12-31 $2
2013-09-30 $2
2013-06-30 $6
2013-03-31 $1
2012-12-31 $1
2012-09-30 $-0
2012-06-30 $-3
2012-03-31 $1
2011-12-31 $5
2011-09-30 $-4
2011-06-30 $-0
2011-03-31 $10
2010-12-31 $5
2010-09-30 $-12
2010-06-30 $-0
2010-03-31 $-3
2009-12-31 $3
2009-09-30 $2
2009-06-30 $-2
2009-03-31 $-5
2008-12-31 $-70
2008-09-30 $-18
2008-06-30 $-6
2008-03-31 $-4
2007-12-31 $6
2007-09-30 $1
2007-06-30 $0
2007-03-31 $274
2006-12-31 $141
2006-09-30 $-15
2006-06-30 $-16
2006-03-31 $-142
2005-12-31 $-3
2005-09-30 $-6
2005-06-30 $-9
2005-03-31 $-18
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.519B $0.186B
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90